Mucoadhesive controlled release dose formulations have grown more popular because of their capacity to adhere and release the loaded medicine over a long period of time. These methods have been used in the past to develop mucoadhesive compositions. For drug delivery devices, mucoadhesion has been a key concern. Characterize, optimize, and assess rosiglitazone maleate microspheres. It is possible to combine mucoadhesion and regulated drug administration with Rosiglitazone Maleate microspheres for the treatment of type 2 diabetes. An emulsion solvent evaporation process was used to manufacture microspheres with mucoadhesive characteristics. Microspheres that were distinct and free-flowing were discovered. They ranged in diameter from 21 to 37 nm. In an in vitro wash-off test, the microspheres displayed good drug trapping and mucoadhesive characteristics. Researchers found that in this investigation, the microspheres released Rosiglitazone Maleate at different rates depending on the polymer used to make them. Up to a 12-hour medication release was seen with F1 and F2 formulations. Most consistently, F1's Carbopol 934 and sodium carboxymethyl cellulose had the greatest mucoadhesive profile and acceptable surface morphology of the many formulations tested. Researchers found that formulation F1 microspheres were the best option for delivering Rosiglitazone Maleate into the gastrointestinal system for an extended period.